15 Analysts Assess Axsome Therapeutics: What You Need To Know

Loading...
Loading...

Throughout the last three months, 15 analysts have evaluated Axsome Therapeutics AXSM, offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 9 6 0 0 0
Last 30D 0 1 0 0 0
1M Ago 3 1 0 0 0
2M Ago 0 2 0 0 0
3M Ago 6 2 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $137.8, a high estimate of $190.00, and a low estimate of $106.00. Witnessing a positive shift, the current average has risen by 7.07% from the previous average price target of $128.70.

Breaking Down Analyst Ratings: A Detailed Examination

An in-depth analysis of recent analyst actions unveils how financial experts perceive Axsome Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Leonid Timashev RBC Capital Raises Outperform $130.00 $127.00
Graig Suvannavejh Mizuho Lowers Buy $106.00 $109.00
David Hoang Citigroup Lowers Buy $125.00 $127.00
Joel Beatty Baird Raises Outperform $112.00 $108.00
Raghuram Selvaraju HC Wainwright & Co. Maintains Buy $190.00 -
Vikram Purohit Morgan Stanley Raises Overweight $115.00 $90.00
Charles Duncan Cantor Fitzgerald Maintains Overweight $107.00 -
Raghuram Selvaraju HC Wainwright & Co. Maintains Buy $190.00 $190.00
Graig Suvannavejh Mizuho Raises Buy $109.00 $108.00
Joon Lee Truist Securities Maintains Buy $150.00 -
Leonid Timashev RBC Capital Raises Outperform $128.00 $123.00
David Hoang Citigroup Raises Buy $127.00 $125.00
Raghuram Selvaraju HC Wainwright & Co. Raises Buy $190.00 $180.00
Raghuram Selvaraju HC Wainwright & Co. Maintains Buy $180.00 -
Joel Beatty Baird Announces Outperform $108.00 -

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Axsome Therapeutics compared to the broader market.
  • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Axsome Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Axsome Therapeutics analyst ratings.

Delving into Axsome Therapeutics's Background

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Breaking Down Axsome Therapeutics's Financial Performance

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Challenges: Axsome Therapeutics's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -20.7%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Axsome Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -91.14%, the company may face hurdles in effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -40.81%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.06%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

The Core of Analyst Ratings: What Every Investor Should Know

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...